Crotoxin - Celtic Biotech Iowa
Alternative Names: CB24; Cytotoxic PLA2; NSC-624244Latest Information Update: 28 Sep 2024
At a glance
- Originator Ventech
- Developer Celtic Biotech Iowa
- Class Antineoplastics; Snake venoms
- Mechanism of Action Apoptosis stimulants; Phospholipase A2 modulators; Protein kinase C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
- Discontinued Cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours in France (IV)
- 07 Sep 2023 Celtic Biotech Iowa plans a phase I trial for Solid tumours (Late-stage disease) in France (IV) (NCT01481532)
- 14 Sep 2022 Crotoxin is still in phase I trials for Solid tumours in France (IV) (Celtic Biotech pipeline, September 2022)